• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster.

作者信息

Silva Almir Ribeiro da, Villas-Boas Lucy Santos, Paula Anderson Vicente de, Tozetto-Mendoza Tania Regina, Honorato Layla, Witkin Steven S, Mendes-Correa Maria Cassia

机构信息

Universidade de São Paulo, Faculdade de Medicina, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.

Universidade de São Paulo, Faculdade de Medicina, Instituto de Medicina Tropical de São Paulo, Laboratório de Investigação Médica em Virologia (LIM-52), São Paulo, São Paulo, Brazil.

出版信息

Rev Inst Med Trop Sao Paulo. 2022 Jun 17;64:e43. doi: 10.1590/S1678-9946202264043. eCollection 2022.

DOI:10.1590/S1678-9946202264043
PMID:35730869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9208660/
Abstract
摘要

相似文献

1
Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster.两剂科兴疫苗接种及一剂辉瑞/ BioNTech mRNA疫苗加强针后针对新冠病毒奥密克戎变异株的中和抗体
Rev Inst Med Trop Sao Paulo. 2022 Jun 17;64:e43. doi: 10.1590/S1678-9946202264043. eCollection 2022.
2
[Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].[同源和异源疫苗接种对严重急性呼吸综合征冠状病毒2奥密克戎变异株的效果：马尼萨杰拉尔·拜亚尔大学医护人员队列研究]
Mikrobiyol Bul. 2023 Apr;57(2):238-251. doi: 10.5578/mb.20239918.
3
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.评估 2 至 3 剂 BNT162b2 mRNA COVID-19 疫苗后针对 SARS-CoV-2 变异株的中和抗体反应。
JAMA Netw Open. 2022 May 2;5(5):e2210780. doi: 10.1001/jamanetworkopen.2022.10780.
4
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
5
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.奥密克戎变异株广泛传播期间，养老院居民接种 COVID-19 追加初级或加强疫苗剂量对预防 SARS-CoV-2 感染的效果-美国，2022 年 2 月 14 日-3 月 27 日。
MMWR Morb Mortal Wkly Rep. 2022 May 6;71(18):633-637. doi: 10.15585/mmwr.mm7118a4.
6
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.Delta-Omicron 混合 mRNA 疫苗加强针可产生针对奥密克戎和其他 SARS-CoV-2 变体的广谱中和抗体。
J Biomed Sci. 2022 Jul 7;29(1):49. doi: 10.1186/s12929-022-00830-1.
7
Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.新冠病毒疫苗应答和针对德尔塔和奥密克戎变异株的第三剂加强针诱导中和抗体的比较分析。
Nat Commun. 2022 May 5;13(1):2476. doi: 10.1038/s41467-022-30162-5.
8
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.针对多发性硬化症患者的 SARS-CoV-2 灭活疫苗和 mRNA 疫苗的安全性和体液免疫应答率。
Mult Scler Relat Disord. 2022 Mar;59:103690. doi: 10.1016/j.msard.2022.103690. Epub 2022 Feb 13.
9
The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine.在拉丁人群中，针对奥密克戎的中和能力有限的抗 SARS-CoV-2 IgG1 和 IgG3 抗体同型在接受多次辉瑞 mRNA 疫苗接种后转向 IgG4。
Viruses. 2024 Jan 26;16(2):187. doi: 10.3390/v16020187.
10
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.科兴新冠疫苗第三针诱导广泛而有效的适应性免疫应答，能识别 SARS-CoV-2 德尔塔和奥密克戎变异株。
Emerg Microbes Infect. 2022 Dec;11(1):1524-1536. doi: 10.1080/22221751.2022.2081614.

本文引用的文献

1
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.在以色列，第四剂 BNT162b2 对奥密克戎的保护作用。
N Engl J Med. 2022 May 5;386(18):1712-1720. doi: 10.1056/NEJMoa2201570. Epub 2022 Apr 5.
2
Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.接种科兴疫苗后对奥密克戎、伽马和德尔塔 SARS-CoV-2 变体产生中和抗体。
Rev Inst Med Trop Sao Paulo. 2022 Feb 25;64:e19. doi: 10.1590/S1678-9946202264019. eCollection 2022.
3
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
4
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine.在已完成灭活疫苗全程免疫的健康成年人中，使用灭活、病毒载体和mRNA新冠疫苗进行第三剂加强免疫的安全性和免疫原性。
Vaccines (Basel). 2022 Jan 6;10(1):86. doi: 10.3390/vaccines10010086.
5
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.在健康成年人中，接种两剂灭活疫苗后接种第三剂病毒载体 COVID-19 疫苗的免疫原性。
Vaccine. 2022 Jan 24;40(3):524-530. doi: 10.1016/j.vaccine.2021.11.083. Epub 2021 Dec 3.